Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis

被引：28

作者：

Lonn E. ^{[1
]}

机构：

[1] Division of Cardiology and Population Health Institute, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton, L8L 2X2, ON

来源：

Current Atherosclerosis Reports | 2002年 / 4卷 / 5期

关键词：

Angiotensin Receptor Blocker; Losartan; Ramipril; Telmisartan; Valsartan;

D O I：

10.1007/s11883-002-0074-7

中图分类号：

学科分类号：

摘要：

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) effectively interfere with the renin-angiotensin system and exert various beneficial actions on cardiac and vascular structure and function, beyond their blood pressure-lowering effects. Randomized, controlled clinical trials have shown that ACE inhibitors improve endothelial function, cardiac and vascular remodeling, retard the anatomic progression of atherosclerosis, and reduce the risk of myocardial infarction, stroke, and cardiovascular death. Therefore, these agents are recommended in the treatment of a wide range of patients at risk for adverse cardiovascular outcomes, including those with coronary disease, prior stroke, peripheral arterial disease, high-risk diabetes, hypertension, and heart failure. ARBs are effective blood pressure-lowering and renoprotective agents and can be used in heart failure in patients who do not tolerate ACE inhibitors. The role of ARBs in the prevention of atherosclerosis and its sequelae is currently under investigation. The use of combined ACE inhibitor plus ARB therapy offers theoretical advantages over the use of each of these agents alone and is also under investigation in large, randomized clinical trials. © 2002, Current Science Inc.

引用

页码：363 / 372

页数：9

共 52 条

[1]

Dzau V.J., Tissue angiotensin and pathobiology of vascular disease—a unifying hypothesis, Hypertension, 37, pp. 1047-1052, (2001)

[2]

Jackson E.K., Renin and angiotensin, Goodman & Gilman’s The Pharmacological Basis of Therapeutics, (2001)

[3]

Dzau V.J., Bernstein K., Celermeier D., Et al., The relevance of tissue angiotensin-converting enzyme

[4]

manifestations in mechanistic and endpoint data, Am J Cardiol, 88, pp. 1L-20L, (2001)

[5]

Blume A., Kaschina E., Unger T., Angiotensin II type 2 receptors: signalling and pathophysiological role, Curr Opin Nephrol Hypertens, 10, pp. 234-246, (2001)

[6]

Tallant E.A., Ferrario C.M., State-of-the-art lecture. Antiproliferative actions of angiotensin-(1–7) in vascular smooth muscle, Hypertension, 34, pp. 950-957, (1999)

[7]

Diet F., Pratt R.E., Berry G.J., Et al., Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease, Circulation, 94, pp. 2756-2767, (1996)

[8]

Cobanian A.V., Haudenschild C.C., Nickerson C., Et al., Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit, Hypertension, 15, pp. 327-331, (1990)

[9]

Aberg G., Ferrer P., Effects of captopril on atherosclerosis in cynomolgus monkeys, J Cardiovasc Pharmacol, 15, pp. S65-S72, (1990)

[10]

Rolland P.H., Carpiot P., Friggi A., Et al., Effects of angiotensin-converting enzyme inhibition with perindopril on hemodynamics, arterial structure and wall rheology in the hindquarters of atherosclerotic mini-pigs, Am J Cardiol, 71, pp. 22E-27E, (1993)

← 1 2 3 4 5 6 →